Derisking Gebr-32a (R-10770)

We have recently identified a promising new target in the treatment of progressive MS. Based on our IP, we were granted a VLAIO innovation mandate phase 1+2. Moreover, we received an AUHL IOF CONCEPT grant that allowed us to hire a consultant for the evaluation of our IP position and strategy with respect to the market potential. The consultant identified gaps in our current results portfolio that need to be addressed to significantly strengthen our strategic position within the framework of 1) a continued collaboration with Rewind Therapeutics, our industrial partner in the VLAIO innovation mandate, 2) investment from or licensing by other interested parties, and/or 3) the creation of a UH spinoff. The required experiments largely concur with data that Rewind Therapeutics requested from us as well, but do not entirely fall within the scope of the VLAIO innovation mandate.

Keywords:Neurodegeneration, Neuropathology

Disciplines:Regenerative medicine not elsewhere classified